Skip to content
Medical Health Aged Care, Science

A treatment for every child with cancer

Australian Academy of Health and Medical Sciences 3 mins read

“Children are not little adults, their cancers are different”

6 September 2023

Photos and videos available at www.scienceinpublic.com.au.

Sydney’s Professor David Ziegler plans to be able to improve treatment for every child with cancer.

He’s working in the clinic to trial treatments for the fatal brain stem tumour DIPG, Diffuse Intrinsic Pontine Glioma.

And he’s driving the development of the national Zero Childhood Cancer Program (ZERO) – to give every child with cancer the best chance of an effective treatment.

Professor Ziegler works at UNSW, Children’s Cancer Institute, and the Kid’s Cancer Centre at Sydney Children’s Hospital.

He will receive the Jian Zhou Medal from the Australian Academy of Health and Medical Sciences together with Melbourne’s Professor Laura Mackay who discovered our body’s first responders – immune T cells in skin, gut and other barriers. Now she’s working out how to both supercharge these cells to better fight infection and cancer, and to calm them down to avoid autoimmune disease.

The medal is named in honour of Professor Jian Zhou who coinvented the cervical cancer vaccine with Professor Ian Frazer. It is awarded annually by the Academy of Health and Medical Sciences for impact in translational medical research.

At every step along the medical research pipeline - from fundamental scientific discoveries to testing radical new treatments - David Ziegler is leading the hunt for new therapies for the deadliest childhood cancers.

As head of the neuro-oncology program at Sydney Children’s Hospital and clinical trials program at the Kids Cancer Centre, David established the first Australian early-phase clinical trials platform to get new children’s cancer therapies into the clinic faster.

“Children are not just little adults. Their cancers are different, and we really need the separate research and clinical trials specific for children with cancer,” says David.

He also set up Australia’s first research into the fatal brain stem tumour DIPG, Diffuse Intrinsic Pontine Glioma. He leads multiple national and international clinical trials for children with DIPG and other aggressive cancers.

David co-developed the national Zero Childhood Cancer Program (ZERO) to bring precision medicine to every child with cancer.

In its first six years, new treatment options have been found for more than 70 per cent of the 1000 young patients enrolled.

“We can analyse every gene in that cancer and get a result back to clinicians within a few weeks, allowing each child to get the best diagnosis, the best prognostic information and the best treatment options,” he says. He aims to make this standard of care available to all the 1,000 children diagnosed with cancer in Australia each year.

His most recent research has led to four clinical trials being established for DIPG, including a first-in-child study, testing different ways of attacking the cancer.

“In 10 years’ time I’d like to be out of a job,” he says.

“I’d like to know that we’re really reaching at 100 per cent cure rate, that there will be no child at diagnosis who is told we don’t have any treatment option.”

David is Head of the Brain Tumour Group at Children’s Cancer Institute and University of New South Wales Conjoint Professor.

Jian Zhou Medal selection committee chair Professor Ian Frazer AC says, “Through his work with patients, in the lab, and in research leadership, Professor Ziegler is transforming children’s cancer treatment.”

AAHMS launched the Jian Zhou Medal in 2020 to recognise rising stars in Australian health and medical science. The award is made possible by a generous donation from the Frazer Family Foundation and the medal is designed and minted by the Royal Australian Mint.

Nominations for the 2023 medal will open in October this year. Read about the Jian Zhou Medal at https://aahms.org/programs/awards/jian-zhou-medal/

About the Academy

The Australian Academy of Health and Medical Sciences is the impartial, authoritative, cross-sector voice of health and medical science in Australia. We advance health and medical research in Australia and its translation into benefits for all, by fostering leadership within our sector, providing expert advice to decision makers, and engaging patients and the public.

We are an independent, interdisciplinary body of Fellows – elected by their peers for their outstanding achievements and exceptional contributions to health and medical science in Australia. Collectively, they are a representative and independent voice, through which we engage with the community, industry and governments.

The Academy is registered with the Australian Charities and Not-for-profits Commission (ACNC) and is endorsed as a deductible gift recipient.


Contact details:

Media: AAHMS Communication Manager Katie Rowney, katie.rowney@aahms.org, 07 3102 7212, 0419 787 551

Niall Byrne, niall@scienceinpublic.com.au, 0417 131 977

Media kit and video at www.scienceinpublic.com.au.

Media

More from this category

  • Medical Health Aged Care
  • 07/10/2024
  • 19:11
Royal Philips

Siloam Hospitals Group and Philips sign AI capability MoU to support Indonesia’s healthcare transformation strategy

October 7, 2024Jakarta, Indonesia and Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Siloam Hospitals Group, Indonesia’s leading private healthcare provider, have signed a Memorandum of Understanding (MoU) to advance AI capabilities and development in the healthcare sector in Indonesia.The strategic collaboration, in partnership with the Universitas Pelita Harapan (UPH) Medical Sciences Group, will focus on capacity building, knowledge sharing, and implementing advanced AI solutions. Leveraging Philips’ AI innovations, the collaboration will help transform clinical care and digital health, enhance healthcare delivery and make the healthcare infrastructure more sustainable. The goal is…

  • Medical Health Aged Care
  • 07/10/2024
  • 17:41
GE HealthCare

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 07/10/2024
  • 14:03
Eastern Health

Eastern Health Clinician leading international autoimmune research

• Clinical Lead of the Eastern Health Multiple Sclerosis and Neuroimmunology Service, Dr Katherine Buzzard is co-chair of the scientific leadership group (SLG) leading an international database designed to study real-world outcomes in Myasthenia Gravis (MG) aimed at improving the quality of life for those battling the disease.• MG is a rare chronic autoimmune disorder whereby antibodies block the signaling between nerves and muscles, resulting in muscle weakness. It affects women and men of all ages.• MGBase is a global MG patient registry collecting longitudinal data to allow biostatisticians and clinicians to do statistical modelling and analysis to improve our…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.